risperidone + divalproex

Risperidone + divalproex is a combination of two pharmaceutical drugs used primarily in the management of psychiatric and neurological disorders, most notably for the treatment of acute manic or mixed episodes associated with bipolar disorder and as adjunctive therapy in schizophrenia. Risperidone is an atypical antipsychotic that acts mainly as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, reducing psychotic symptoms and stabilizing mood. Divalproex sodium (divalproex) is an anticonvulsant and mood stabilizer that increases brain concentrations of gamma-aminobutyric acid (GABA), exerting antimanic, anticonvulsant, and antimigraine effects. The combination may be prescribed to enhance therapeutic efficacy or target specific symptom domains such as hostility or agitation in acute psychosis. Clinical studies suggest this combination can provide more rapid improvement in manic symptoms compared to monotherapy with either agent alone[2][4][5]. However, co-administration requires careful monitoring due to potential pharmacodynamic interactions leading to increased risk of central nervous system depression (drowsiness, dizziness) and other adverse effects[1][8].

Other names

divalproex ER + risperidonevalproic acid + risperidone